Metabolic modulation to improve MSC expansion and therapeutic potential for articular cartilage repair

Ching Ann Tee,Daniel Ninio Roxby,Rashidah Othman,Vinitha Denslin,Kiseer Sideeq Bhat,Zheng Yang,Jongyoon Han,Lisa Tucker-Kellogg,Laurie A. Boyer
DOI: https://doi.org/10.1186/s13287-024-03923-w
2024-09-20
Stem Cell Research & Therapy
Abstract:Articular cartilage degeneration can result from injury, age, or arthritis, causing significant joint pain and disability without surgical intervention. Currently, the only FDA cell-based therapy for articular cartilage injury is Autologous Chondrocyte Implantation (ACI); however, this procedure is costly, time-intensive, and requires multiple treatments. Mesenchymal stromal cells (MSCs) are an attractive alternative autologous therapy due to their availability and ability to robustly differentiate into chondrocytes for transplantation with good safety profiles. However, treatment outcomes are variable due to donor-to-donor variability as well as intrapopulation heterogeneity and unstandardized MSC manufacturing protocols. Process improvements that reduce cell heterogeneity while increasing donor cell numbers with improved chondrogenic potential during expansion culture are needed to realize the full potential of MSC therapy.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?